Showing results (931-940 of 1,155) with videos related to
Sort By:
Pageof 116
Gynecologic Oncology|March 13, 2021
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)Megan E Buechel, Danielle Enserro, Robert A Burger, et al.Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.Surgical Endoscopy|September 16, 2024
Patient-reported outcomes during first-line palliative systemic therapy alternated with pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-II)Vincent C J van de Vlasakker, Paulien Rauwerdink, Koen P B Rovers, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 27, 2014
First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinomaIrene A Burger, Sabine Zitzmann-Kolbe, Jan Pruim, et al.Scientific Reports|October 17, 2014
Probing excitonic states in suspended two-dimensional semiconductors by photocurrent spectroscopyA R Klots, A K M Newaz, Bin Wang, et al.CPT: Pharmacometrics & Systems Pharmacology|April 18, 2024
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal originPascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, et al.Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.Journal of the National Cancer Institute|December 11, 2019
Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative AnalysisEmily A Burger, Inge M C M de Kok, Emily Groene, et al.Pageof 116